Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia
Authors' conclusion
In this study, there was a modest but statistically significant reduction in DAS28-CRP at 3 months for patients receiving TOF compared with those receiving ADA and no difference between treatment groups at 9 months.
Study context
- Population
- Australian adults ≥18 years with rheumatoid arthritis (RA) in the OPAL data set, new b/tsDMARD users initiating ADA or tofacitinib (TOF) between October 1, 2015, and April 1, 2021, with ≥1 DAS28-CRP component recorded
- Participants
- 842 adults
- Comparison
- Tofacitinib vs adalimumab
- ADAn = 569reference
- TOFn = 273
- Primary endpoint
- Mean DAS28-CRP (weighted)
- Follow-up
- 3 months
Methodological detailstarget trial emulation, observational (OPAL data set), stable balancing weights, multiple imputation of missing DAS28-CRP
- Target trial emulation
- Observational (OPAL data set)
- Stable balancing weights
- Multiple imputation of missing DAS28-CRP
Primary result
As reported in the abstract
Mean DAS28-CRP; average treatment effect (difference in means, TOF minus ADA), weighted
TOF
2.4
mean · 95% CI 2.2–2.5
ADA
2.6
mean · 95% CI 2.5–2.7
Further findings
Mean
| Outcome | ADA | TOF |
|---|---|---|
| Mean DAS28-CRP; average treatment effect (TOF minus ADA), weighted (main outcome, 9-month time point) · stable balancing weights | 2.3 (95% CI 2.2–2.4) | 2.3 (95% CI 2.1–2.4) |
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparative Effectiveness of Adalimumab vs Tofacitinib in Patients With Rheumatoid Arthritis in Australia. JAMA Netw Open. Published 1 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →